User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

1295

Interactions with Platform & by Email *

INTERACTIONS

233

Unique # Participated *

PARTICIPANTS

52

Responses Validated *

VALIDATIONS

13

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
Quantitative Techniques & Analytics.....I-2
  
   Product Definitions and Scope of Study.....I-3
Carotid Stents.....I-3
  
   Carotid Stents – A Nascent Market.....II-1
Current and Future Analysis.....II-1
US – Picking Pace.....II-1
1$100
   Factors Driving Carotid Stents Market.....II-2
Clinical Trials & Regulatory Approvals to Accelerate Adoption.....II-2
Broader Application of CAS.....II-2
Benefiting From Less-Invasive Nature of Procedure.....II-2
Acceptance by Various Medical Specialties.....II-2
1$100
   Market Challenges.....II-3
Absence of Sufficient Clinical Data.....II-3
Surgeons Wary of High-Risk CAS Procedures.....II-3
Reimbursement Coverage Issue Hurdles Widespread Adoption.....II-3
Fighting for CAS Domain.....II-3
1$100
   Training and Certification of Surgeons – A Major Hurdle.....II-4
Stenting Procedure for Transient Ischemic Attacks – A Continuing Dilemma.....II-4
1$100
   Table 1: Worldwide Carotid Stents Market (2006-2007E): Market Share of Leading Players by Revenues for Boston Scientific, Abbott Vascular/Guidant, Johnson & Johnson/Cordis, Medtronic and Others (includes corresponding Graph/Chart).....II-5
1$300
   Carotid Stents – An Introduction.....II-6
How is Carotid Stenting Helpful?.....II-6
Carotid Stents – A Viable Alternative to Surgical Procedures.....II-6
1$100
   Carotid Stenting Lowers Depression Symptoms!!!.....II-7
Embolic Protection Devices.....II-7
Filter-Based EPD Systems.....II-7
Balloon Occlusion Devices.....II-7
1$100
   Basic Carotid Stents Products.....II-8
Stent Design.....II-8
Carotid Stents of Major Companies Available in the Market.....II-8
1$100
   Carotid Stents Under Development.....II-9
Diagnosis of Carotid Artery Blockage.....II-9
1$100
   Eligibility Criteria for Carotid Stenting Procedure.....II-10
Potential Candidates for Carotid Stenting.....II-10
Patients with High Surgical Risk.....II-10
Non-Candidates for Carotid Stenting.....II-10
Risk Factors Associated with Carotid Stenting Procedures.....II-10
1$100
   Carotid Artery Stenting (CAS) - The Procedure.....II-11
Catheter Insertion Via Femoral Artery.....II-11
1$100
   Advantages of the Procedure.....II-12
Post-Stenting Complications.....II-12
1$100
   Cerebrovascular Disease.....II-13
Carotid Artery Disease.....II-13
Major Symptoms.....II-13
Carotid Artery Stenosis.....II-13
1$100
   Atherosclerosis.....II-14
Treatment Procedures for Carotid Artery Disease.....II-14
Carotid Endarterectomy (CEA).....II-14
Drawbacks of CEA Procedure.....II-14
1$100
   Carotid Artery Stenting (CAS).....II-15
CAS Versus CEA.....II-15
1$100
   Table 2: Worldwide Carotid Interventions (2006-2008E)): Percentage Breakdown of Number of Procedures for Carotid Endarterectomy and Carotid Stenting (includes corresponding Graph/Chart).....II-16
Comparative Study of CAS and CEA Devices.....II-16
Benefits of CAS over CEA.....II-16
1$300
   Drawbacks for CAS Penetration.....II-17
Risks Associated with CEA and CAS.....II-17
1$100
   Clinical Trials – Key to Higher Adoption of Carotid Stents.....II-18
Major Clinical Trials & Stent Devices Used.....II-18
1$100
   Guidant’s CAPTURE Study.....II-19
CAPTURE Study Results Hold Promise for Asymptomatic Patients.....II-19
1$100
   Boston Scientific’s BEACH Trial.....II-20
Abbott’s ACT I Trial.....II-20
CREST Clinical Trial.....II-20
1$100
   CREST Closes Lead-in and Randomized Phase Recruitment.....II-21
J&J’s SAPPHIRE Clinical Trial.....II-21
SAPPHIRE Study Proves Effectiveness of CAS in High-Risk Patients.....II-21
1$100
   Other Trials.....II-22
Medtronic’s MAVErIC Trials Validate the Efficiency of Exponent Carotid Stent.....II-22
University of Massachusetts Conduct CAS Efficacy Study in Elderly Patients.....II-22
CaRESS Study.....II-22
1$100
   KNC Obtains Expanded CE Mark Clearance for TriActiv® ProGuard™.....II-23
FDA Approves Protege® RX Carotid Stent from ev3.....II-23
1$100
   Abbott Introduces Emboshield® PRO Embolic Protection System in Europe.....II-24
Cordis Gains FDA Approval for PRECISE® & ANGIOGUARD® Devices.....II-24
Medtronic Obtains CE Mark Approval for Exponent® RX Carotid Stent.....II-24
1$100
   FDA Approves Boston Scientific’s FilterWire EZ™ Embolic Protection System.....II-25
Abbott's Xact® Carotid Stent Receives FDA Approval.....II-25
EndoTex’s NexStent™ Receives CE Mark Approval.....II-25
KNC Seeks FDA Approval for TriActiv LFX Trial.....II-25
1$100
   Guidant's RX ACCULINK™ Carotid Stent System Gets FDA Clearance.....II-26
ev3’s Protege GPS Receives CE Mark Approval.....II-26
Medtronic’s Interceptor® PLUS Carotid Filter System Receives CE Mark Approval.....II-26
Guidant Unveils RX Accunet Embolic Protection System in European Market.....II-26
1$100
   Guidant Rolls Out ACCULINK™ Carotid Stent System for European Market.....II-27
1$100
   Boston Scientific Acquires EndoTex.....II-28
Boston Scientific and Guidant Merge Operations; Abbott Acquires Guidant’s Vascular
  Business.....II-28
1$100
   Lumen Commences EPIC Feasibility Study.....II-29
Boston Scientific Exclusively Distributes EndoTex’s NexStent™ Carotid Stent.....II-29
1$100
   Abbott Vascular (US).....II-30
Boston Scientific Corporation (USA).....II-30
1$100
   ev3, Inc. (USA).....II-31
Johnson & Johnson (USA).....II-31
Cordis Corporation (USA).....II-31
1$100
   Kensey Nash Corporation (USA).....II-32
Medtronic, Inc. (USA).....II-32
1$100
   Table 3: World Recent Past, Current & Future Analysis for Carotid Stents by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed with Annual Number of Carotid Stent Procedures in Thousands for Years 2004 through 2012 (includes corresponding Graph/Chart).....II-33

Table 4: World 9-Year Perspective for Carotid Stents by Geographic Region – Percentage Breakdown by Number of Carotid Stent Procedures for US, Europe and Rest of World Markets for Years 2004, 2007 & 2012 (includes corresponding Graph/Chart).....II-33
1$300
   Table 5: World Recent Past, Current & Future Analysis for Carotid Stents by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed with Annual Revenues in US$ Million for Years 2004 through 2012 (includes corresponding Graph/Chart).....II-34

Table 6: World 9-Year Perspective for Carotid Stents by Geographic Region – Percentage Breakdown by Annual Revenues for US, Europe and Rest of World Markets for Years 2004, 2007 & 2012 (includes corresponding Graph/Chart).....II-34
1$300
   A. Market Analysis.....III-1
Overview.....III-1
Current and Future Analysis.....III-1
Factors Affecting Growth.....III-1
Reimbursement Scenario for CAS.....III-1
1$100
   Restricted Reimbursement Coverage Limits CAS Penetration .....III-2
CMS Proposes Expanded Reimbursement Coverage for Carotid Stenting.....III-2
1$100
   Absence of Regulatory Approvals – A Major Challenge.....III-3
Clinical Trials – Key to Higher Adoption of Carotid Stents.....III-3
Latent Demand.....III-3
Key Statistics.....III-3
Major Carotid Stents & EPDs in the Market.....III-3
1$100
   US Carotid Stents Market – A Gradual Growth.....III-4 1$100
   Table 7: Carotid Interventions in the US (2006-2008): Percentage Breakdown of Number of Procedures by Carotid Endarterectomy and Carotid Stenting (includes corresponding Graph/Chart).....III-5
Trends and Issues.....III-5
Convenience in Deployment & Use – Critical for Higher Adoption.....III-5
Rapid Exchange Capabilities Facilitate Effective Control Over Procedures.....III-5
Carotid Stents Assume the Role of Memory Boosters.....III-5
1$150
   Competitive Landscape.....III-6
Table 8: US Carotid Stents Market (2006-2007): Market Share of Leading Players by Revenues for Boston Scientific, Guidant, Cordis/J&J, Medtronic and Others (includes corresponding Graph/Chart).....III-6
1$150
   Product Launches/Approvals.....III-72$200
   Strategic Corporate Developments.....III-91$100
   Focus on Select Players.....III-10
Abbott Vascular.....III-10
1$100
   Boston Scientific Corporation.....III-11
ev3, Inc......III-11
1$100
   Johnson & Johnson.....III-12
Cordis Corporation.....III-12
Kensey Nash Corporation.....III-12
1$100
   Medtronic, Inc......III-13
B. Market Analysis.....III-13
Table 9: US Recent Past, Current & Future Analysis for Carotid Stents Market Independently Analyzed with Annual Number of Carotid Stent Procedures in Thousands for Years 2004 through 2012 (includes corresponding Graph/Chart).....III-13
1$150
   Table 10: US Recent Past, Current & Future Analysis for Carotid Stents Market Independently Analyzed with Annual Revenues in US$ Million for Years 2004 through 2012 (includes corresponding Graph/Chart).....III-14
1$150
   A. Market Analysis.....III-15
Current and Future Analysis.....III-15
European Carotid Stents Market – An Overview.....III-15
ELOCAS Study.....III-15
CEA Versus CAS.....III-15
1$100
   Table 11: European Vascular Interventions Market (2004-2006E): Percentage Breakdown by Number of Procedures for Carotid Artery Stenting and Carotid Endarterectomy (includes corresponding Graph/Chart).....III-16
Product Launches/Approvals.....III-16
2$300
   Strategic Corporate Development.....III-181$100
   B. Market Analytics.....III-19
Table 12: European Recent Past, Current & Future Analysis for Carotid Stents Market Independently Analyzed with Annual Number of Carotid Stent Procedures in Thousands for Years 2004 through 2012 (includes corresponding Graph/Chart).....III-19

Table 13: European Recent Past, Current & Future Analysis for Carotid Stents Market Independently Analyzed with Annual Revenues in US$ Million for Years 2004 through 2012 (includes corresponding Graph/Chart).....III-19
1$150
   A. Market Analysis.....III-20
Current and Future Analysis.....III-20
Carotid Stenting Scenario in India.....III-20
1$100
   B. Market Analytics.....III-21
Table 14: Rest of World Recent Past, Current & Future Analysis for Carotid Stents Market Independently Analyzed with Annual Number of Carotid Stent Procedures in Thousands for Years 2004 through 2012 (includes corresponding Graph/Chart).....III-21

Table 15: Rest of World Recent Past, Current & Future Analysis for Carotid Stents Market Independently Analyzed with Annual Revenues in US$ Million for Years 2004 through 2012 (includes corresponding Graph/Chart).....III-21
1$150